Dysregulation of the CDKN2A locus, due to either mutation or methylation, which encodes p16 and p19, has been reported in several subtypes of human sarcomas; consequently we examined if abrogation of this tumor suppressor in the RCAS-TVA system would promote sarcoma formation [23], [24]. Here, CDKN2A is linked to sarcoma.